"We remain on track to report primary efficacy and safety data plus interim data from the open-label extension ... compared to $1.1 million and $3.4 million for the same periods in 2023. Net Loss: Net ...
Tango Therapeutics is in the penalty box, as investors are losing patience and are disappointed to learn TNG908 has limited efficacy in Glioblastoma Multiforme after the trial has been running for 2.5 ...